[go: up one dir, main page]

WO2005117993A3 - Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers - Google Patents

Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers Download PDF

Info

Publication number
WO2005117993A3
WO2005117993A3 PCT/US2005/019630 US2005019630W WO2005117993A3 WO 2005117993 A3 WO2005117993 A3 WO 2005117993A3 US 2005019630 W US2005019630 W US 2005019630W WO 2005117993 A3 WO2005117993 A3 WO 2005117993A3
Authority
WO
WIPO (PCT)
Prior art keywords
efficacy
cancer
treatment
adenoviral vectors
improved safety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/019630
Other languages
English (en)
Other versions
WO2005117993A2 (fr
Inventor
Thomas J Wickham
Masaki Akiyama
Selva Murgesan
David Einfeld
Tomoyuki Abe
Hiroshi Yoshida
Osamu Yamada
Hiromasa Araki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuso Pharmaceutical Industries Ltd
Genvec Inc
Original Assignee
Fuso Pharmaceutical Industries Ltd
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Industries Ltd, Genvec Inc filed Critical Fuso Pharmaceutical Industries Ltd
Publication of WO2005117993A2 publication Critical patent/WO2005117993A2/fr
Publication of WO2005117993A3 publication Critical patent/WO2005117993A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode permettant de détruire les cellules tumorales dans la cavité péritonéale d'un mammifère. Ce procédé consiste à administrer au mammifère une dose d'un vecteur adénoviral à réplication déficiente comprenant (a) une séquence d'acide nucléique exogène codant pour un TNf-α humain, lié de manière fonctionnelle à un promoteur sélectif dirigé sur les cellules tumorales, (b) une protéine fibreuse présentant une disruption du site de liaison natif du récepteur CAR, et (c) une protéine base du penton présentant une disruption du site natif de liaison de l'intégrine.
PCT/US2005/019630 2004-06-04 2005-06-03 Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers Ceased WO2005117993A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57711704P 2004-06-04 2004-06-04
US60/577,117 2004-06-04

Publications (2)

Publication Number Publication Date
WO2005117993A2 WO2005117993A2 (fr) 2005-12-15
WO2005117993A3 true WO2005117993A3 (fr) 2006-06-15

Family

ID=35463367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019630 Ceased WO2005117993A2 (fr) 2004-06-04 2005-06-03 Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers

Country Status (1)

Country Link
WO (1) WO2005117993A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
US10420820B2 (en) 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
CA3013637A1 (fr) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Dosage a haut debit pour mesurer la cinetique de replication d'un adenovirus
ES2933174T3 (es) 2016-02-23 2023-02-02 Salk Inst For Biological Studi Expresión génica exógena en adenovirus terapéutico para mínimo impacto sobre la cinética viral
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
KR20200140848A (ko) 2018-04-09 2020-12-16 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 복제 속성이 향상된 종양살상형 아데노바이러스 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877010A (en) * 1994-05-02 1999-03-02 University Of Washington Thymidine kinase mutants
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877010A (en) * 1994-05-02 1999-03-02 University Of Washington Thymidine kinase mutants
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRIPE T.P. ET AL: "Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells", CANCER RESEARCH, vol. 61, 2001, pages 2953 - 2960, XP002969170 *
MIZUGUCHI H. ET AL: "CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice", GENE THERAPY, vol. 9, 2002, pages 769 - 776, XP002995191 *

Also Published As

Publication number Publication date
WO2005117993A2 (fr) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005086922A3 (fr) Adenovirus oncolytique dote de genes therapeutiques
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
WO2007070392A3 (fr) Vecteurs d'expression adenovirale
GB0911870D0 (en) Optimised coding sequence and promoter
Markelc et al. In vivo molecular imaging and histological analysis of changes induced by electric pulses used for plasmid DNA electrotransfer to the skin: a study in a dorsal window chamber in mice
SI1711518T1 (sl) Ĺ impanzji adenovirusni nosilci cepiva
WO2000055345A3 (fr) Therapie du cancer au moyen de cellules d'insectes contenant des genes codant un baculovirus recombinant
WO2003023000A3 (fr) Fragments d'adn lineaires destines a l'expression genetique
WO2020186207A3 (fr) Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii
WO2006050211A3 (fr) Therapie genique a base de proteine decarboxylase d'acide glutamique a administration peripherique pour lutter contre la douleur engendree par un traumatisme medullaire
EP1455840A4 (fr) Traitement du cancer humain avec vector adenoviral tnf-alpha
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2007092944A8 (fr) Compositions et procedes impliquant une therapie de gene et une modulation de proteasome
WO2005117993A3 (fr) Methode permettant une utilisation plus sure et plus efficace de vecteurs adenoviraux pour le traitement des cancers
WO2008134752A3 (fr) Méthodes et compositions pour traiter le cancer
DK1144600T3 (da) Akt-3-nukleinsyre, polypeptider og anvendelser deraf
GB0418388D0 (en) Cell therapy
Ternovoi et al. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
WO2004092212A3 (fr) Antigene tumoral bfa-5 pour la prevention et/ou le traitement du cancer
WO2005111204A3 (fr) Protéine de ligase de forssman porcine, adn complémentaire, organisation génomique et région de réglementation
WO2013012771A3 (fr) Applications cliniques d'une injection d'adénovirus recombinant codant pour l'endostatine humaine (e10a)
WO2010006136A3 (fr) Ciblage d'adénovirus
WO2008013928A3 (fr) Traitement du cancer par administration de gène interféron en association avec un inhibiteur tgf-beta
WO2006103494A3 (fr) Molecules antivirales bifonctionnelles, procedes de construction et procedes de traitement de cancer viro-induit a l'aide desdites molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase